Cytopoint
سايتوبوينت
Cytopoint (lokivetmab) is an innovative caninized monoclonal antibody (mAb) that specifically targets and neutralizes canine interleukin-31 (IL-31), a key cytokine involved in triggering pruritus and allergic inflammation in atopic and allergic dermatitis in dogs.
Dosage Form
Injection
Product Type
Biological
Manufacturer
Package
Single-dose vials containing 10 mg, 20 mg, 30 mg, or 40 mg/mL lokivetmab in cartons of 5 or 10 vials
Dosages
| Species | Dosage | Route | Duration |
|---|---|---|---|
| Dog | Minimum 2.0 mg/kg (0.9 mg/lb) body weight | Subcutaneous (SC) | Administer once every 4 to 8 weeks as needed |
Withdrawal Periods
No withdrawal information available.
Indications
-
Treatment of clinical signs associated with atopic dermatitis in dogs.
-
Treatment of clinical signs associated with allergic dermatitis in dogs of any age.
Contraindications
-
Do not use in dogs with known hypersensitivity to lokivetmab or any of the excipients.
Precautions
-
Can be safely used concurrently with other medications including antimicrobial, antiparasitic, and anti-inflammatory therapies.
-
Safety has not been evaluated in breeding, pregnant, or lactating dogs.
-
Monoclonal antibodies are eliminated via normal protein degradation pathways without hepatic or renal clearance involvement.
Side Effects
-
Adverse reactions are rare and similar to placebo: lethargy, vomiting, hyperexcitability, injection site pain or swelling, and dermatitis.
Images
Documents
-
Download
Cytopoint Prescribing Information
Leaflet
Active Ingredients
-
Lokivetmab
10 mg/vial (10, 20, 30, 40 mg)
Diseases
No diseases linked.
Related Products
No data available
Information has not been added yet.
Related Products By Active Ingredient
No data available
Information has not been added yet.
Companies
-
Zoetis
Manufacturer
Alternatives
No alternatives available.